<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="nefarious purposes. Public health responses effective in natural outbreaks of" exact="infectious disease" post="may not be sufficient to deal with the severe"/>
 <result pre="purposes. Public health responses effective in natural outbreaks of infectious" exact="disease" post="may not be sufficient to deal with the severe"/>
 <result pre="release of such agents. One important aspect of countermeasures against" exact="viral" post="biothreat agents are the antiviral treatment options available for"/>
 <result pre="a special session on the development of drugs to treat" exact="infections" post="with viruses currently perceived as a threat to societies"/>
 <result pre="use or still under development. Keywords Medical biodefense Antiviral BSL3/4" exact="viral" post="pathogens Funding BundeswehrSTAN 59-2016-01BugertJ. J. Introduction Antiviral compounds effective"/>
 <result pre="pathogens Funding BundeswehrSTAN 59-2016-01BugertJ. J. Introduction Antiviral compounds effective in" exact="infections" post="caused by tropical and vector-borne viruses were a neglected"/>
 <result pre="or have made it to the market. Biodefense relevance While" exact="infections" post="with arthropod-borne and tropical viruses are fairly common in"/>
 <result pre="particularly for dangerous biological agents. This review will focus on" exact="viral" post="agents that fit into this category, briefly discussing their"/>
 <result pre="treatment options available or in the pipeline. Public health relevance" exact="Viral" post="hemorrhagic fevers (VHFs) cause the highest mortality in human"/>
 <result pre="cause the highest mortality in human hosts among all known" exact="viral" post="agents. Encephalitides and severe respiratory infections caused by a"/>
 <result pre="human hosts among all known viral agents. Encephalitides and severe" exact="respiratory" post="infections caused by a range of viruses are other"/>
 <result pre="hosts among all known viral agents. Encephalitides and severe respiratory" exact="infections" post="caused by a range of viruses are other diseases"/>
 <result pre="with often severe clinical outcomes. The recent emergence of such" exact="infections" post="from geographical hotspots is mainly a consequence of the"/>
 <result pre="of the rapid development of ground and air transport. Vector-borne" exact="infections" post="are also affected by climate change. Large-scale outbreaks were"/>
 <result pre="affected by climate change. Large-scale outbreaks were first described for" exact="Monkeypox virus" post="in central Africa in the 1970s [117], while outbreaks"/>
 <result pre="1970s [117], while outbreaks of mosquito-borne Chikungunya virus [85] and" exact="Dengue" post="virus infections in the Indian Ocean islands were seen"/>
 <result pre="while outbreaks of mosquito-borne Chikungunya virus [85] and Dengue virus" exact="infections" post="in the Indian Ocean islands were seen mostly in"/>
 <result pre="fatalities [37], has attracted extensive media attention. The rapid and" exact="uncontrolled" post="spread of Ebola fever in Africa has been considered"/>
 <result pre="for several reasons, one of them being the risk that" exact="variola" post="virus might be brought back with the methods of"/>
 <result pre="the early 2000s for fear that Iraq might have weaponized" exact="smallpox" post="virus (which it had not, as was revealed later"/>
 <result pre="no licensed drug was available at the time to treat" exact="infections" post="with variola virus, a drug effective against orthopoxviruses, tecovirimat,"/>
 <result pre="drug was available at the time to treat infections with" exact="variola" post="virus, a drug effective against orthopoxviruses, tecovirimat, has recently"/>
 <result pre="States Federal Drug Administration [55]. Smallpox as an exclusively human" exact="infection" post="was eradicated by vaccination, but this is impossible for"/>
 <result pre="eradicated by vaccination, but this is impossible for zoonoses like" exact="yellow fever," post="which has a number of non-human reservoir hosts. This"/>
 <result pre="is an important distinction, and in the case of an" exact="acute" post="zoonotic viral infection, post-exposure antiviral treatment of the unvaccinated"/>
 <result pre="important distinction, and in the case of an acute zoonotic" exact="viral infection," post="post-exposure antiviral treatment of the unvaccinated is a potentially"/>
 <result pre="Unfortunately, the public health repository of antiviral countermeasures for such" exact="infections" post="is woefully small. VHFs are caused by infection with"/>
 <result pre="for such infections is woefully small. VHFs are caused by" exact="infection" post="with RNA viruses. The standard of treatment for RNA"/>
 <result pre="with RNA viruses. The standard of treatment for RNA virus" exact="infections" post="where it shows efficacy, is ribavirin, developed in 1963"/>
 <result pre="in 1963 [32]. Where possible, early start of treatment of" exact="acute" post="virus infections gives the best results and, in this"/>
 <result pre="[32]. Where possible, early start of treatment of acute virus" exact="infections" post="gives the best results and, in this context, accurate"/>
 <result pre="was demonstrated in the recent Ebola outbreaks in West- and" exact="Central" post="Africa. However, the need for new antiviral agents had"/>
 <result pre="David Freestone as early as 1985 [47]. While many virus" exact="infections" post="are asymptomatic, new or improved antiviral drugs are needed"/>
 <result pre="there are no FDA-approved antivirals for Ebola or the causative" exact="viral" post="agents of many other viral hemorrhagic fevers, viral encephalitides,"/>
 <result pre="for Ebola or the causative viral agents of many other" exact="viral" post="hemorrhagic fevers, viral encephalitides, and respiratory infections. Few therapeutic"/>
 <result pre="the causative viral agents of many other viral hemorrhagic fevers," exact="viral" post="encephalitides, and respiratory infections. Few therapeutic interventions are available"/>
 <result pre="agents of many other viral hemorrhagic fevers, viral encephalitides, and" exact="respiratory" post="infections. Few therapeutic interventions are available except for supportive"/>
 <result pre="between research and industry, and preparedness for the treatment of" exact="infections" post="with biodefense-related viruses followed. Further contributions outlined the methodical"/>
 <result pre="of virtual candidate antiviral compounds in in silico models against" exact="viral" post="protein targets reduces the number of compounds by four"/>
 <result pre="the pathogenic traits of the viruses of interest (e.g., U138" exact="glioblastoma" post="cells for encephalitis viruses). This usually results in another"/>
 <result pre="of the viruses of interest (e.g., U138 glioblastoma cells for" exact="encephalitis" post="viruses). This usually results in another reduction of candidate"/>
 <result pre="carried out, either by the use of enzymatic assays for" exact="viral" post="enzyme targets (Silvestri—MBDC-2018- GO3) or by induction of resistant"/>
 <result pre="into pharmacokinetics testing (rodent models), and into animal models of" exact="viral" post="infections (Step 5). Here a dramatic rate of attrition"/>
 <result pre="pharmacokinetics testing (rodent models), and into animal models of viral" exact="infections" post="(Step 5). Here a dramatic rate of attrition leads"/>
 <result pre="[79]. To further select compounds prior to animal testing, complex" exact="infection" post="models, including in vitro 3D models, are currently the"/>
 <result pre="much research in the antivirals field [77]. Functional models of" exact="virus infection" post="at barriers, and the effect of antivirals on the"/>
 <result pre="research in the antivirals field [77]. Functional models of virus" exact="infection" post="at barriers, and the effect of antivirals on the"/>
 <result pre="the barrier, give an indication of antiviral effects on typical" exact="viral" post="pathogenesis, e.g., encephalitis viruses that are being tested on"/>
 <result pre="an indication of antiviral effects on typical viral pathogenesis, e.g.," exact="encephalitis" post="viruses that are being tested on models of the"/>
 <result pre="vitro functional models of antivirals efficacy in vivo, particularly using" exact="primary" post="human organotypic cells, would also result in a significant"/>
 <result pre="between Cardiff University and IMB into prophylaxis and treatment of" exact="infections" post="caused by viral biothreat agents, which is funded by"/>
 <result pre="and IMB into prophylaxis and treatment of infections caused by" exact="viral" post="biothreat agents, which is funded by SER CYMRU/MRC and"/>
 <result pre="steps from molecular design to in vitro testing in complex" exact="infection" post="models. Talks at MBDC 2018 included different examples of"/>
 <result pre="and prodrugs against arboviruses (Bassetto-MBDC-2018-GO2), Cima-4, Den-12, MB-124, tick borne" exact="encephalitis" post="(TBEV) polymerase inhibitor nucleoside analogues with superior activity in"/>
 <result pre="(TBEV) polymerase inhibitor nucleoside analogues with superior activity in the" exact="central nervous system" post="(CNS) cells compared to sofosbuvir (Bugert-MBDC-2018-GO3), novel protease inhibitors"/>
 <result pre="flaviviruses (Tscherne-MBDC-2018-GP5), and MoA studies on Cf2642 inhibiting macropinocytosis of" exact="measles" post="and poxviruses for use as synergistic cell-targeting antiviral along"/>
 <result pre="I–III clinical studies. Subsections give a brief overview of the" exact="viral" post="agents in the order of relevance for biodefense, the"/>
 <result pre="anti-inflammatory drug, Phase clinical trial phase I to III, Pol" exact="viral" post="polymerase, Prot viral protease, Vs. versus, + more viruses, not listed"/>
 <result pre="clinical trial phase I to III, Pol viral polymerase, Prot" exact="viral" post="protease, Vs. versus, + more viruses, not listed Poxviridae Variola virus"/>
 <result pre="18th century as a biological warfare agent by British and" exact="American" post="forces in North America [36], and remains on the"/>
 <result pre="in only two designated laboratories in Russia and the US." exact="Monkeypox virus" post="(BSL-3), a zoonotic agent causing sequelae similar to smallpox"/>
 <result pre="Monkeypox virus (BSL-3), a zoonotic agent causing sequelae similar to" exact="smallpox" post="but less fatal, is endemic in central Africa (Democratic"/>
 <result pre="to the UK were travel-related. Poxviruses are transmitted by contact" exact="infection" post="and via the respiratory tract, causing a systemic infection"/>
 <result pre="travel-related. Poxviruses are transmitted by contact infection and via the" exact="respiratory" post="tract, causing a systemic infection in humans and animals."/>
 <result pre="by contact infection and via the respiratory tract, causing a" exact="systemic" post="infection in humans and animals. Smallpox virus infection leads"/>
 <result pre="contact infection and via the respiratory tract, causing a systemic" exact="infection" post="in humans and animals. Smallpox virus infection leads to"/>
 <result pre="tract, causing a systemic infection in humans and animals. Smallpox" exact="virus infection" post="leads to a fatal multiorgan failure syndrome within 7–14"/>
 <result pre="causing a systemic infection in humans and animals. Smallpox virus" exact="infection" post="leads to a fatal multiorgan failure syndrome within 7–14"/>
 <result pre="animals. Smallpox virus infection leads to a fatal multiorgan failure" exact="syndrome" post="within 7–14 days, in complicated cases with a hemorrhagic"/>
 <result pre="syndrome within 7–14 days, in complicated cases with a hemorrhagic" exact="syndrome" post="and CNS involvement. Smallpox has played a role in"/>
 <result pre="in clinical use as a parenteral treatment in severe OPV" exact="infections" post="was cidofovir, a bisphosphonate developed at REGA, in Belgium"/>
 <result pre="inhibitor tecovirimat (ST-246, TPOXX®) has been independently developed to treat" exact="smallpox" post="infections and has been FDA approved since 2018. Tecovirimat"/>
 <result pre="tecovirimat (ST-246, TPOXX®) has been independently developed to treat smallpox" exact="infections" post="and has been FDA approved since 2018. Tecovirimat has"/>
 <result pre="have shown interesting antiviral activity against OPV in in vitro" exact="infection" post="models [27, 153] (Table 1). Filoviridae Filoviruses are category"/>
 <result pre="of human patients. Ebola and Marburg viruses (EBOV/MARV) cause severe" exact="viral" post="hemorrhagic fevers with hematemesis, bloody diarrhea, prostration and case"/>
 <result pre="used in the VSV-EBOV vaccine, which is 70–100% effective preventing" exact="disease" post="in exposed and vaccinated individuals and has been approved"/>
 <result pre="The endosomal Nieman Pick C1 protein, also relevant in flavivirus" exact="infections" post="[114] and the TIM-1 (HAVCR1) receptor on the surface"/>
 <result pre="receptor on the surface of T cells, also relevant for" exact="hepatitis" post="C virus (HCV) entry [73], are potential targets for"/>
 <result pre="in non-human primates likely by chain termination [144], but showed" exact="lower" post="efficacy in the clinical trial compared to monoclonal antibody-based"/>
 <result pre="Japan, and since found to be a broad-spectrum inhibitor of" exact="viral" post="RNA polymerases [34, 49]. T705 and the related pyrazine-carboxamide"/>
 <result pre="&quot;Alphaviridae.&quot; FDA approval for use of favipiravir to treat filovirus" exact="infections" post="is pending. Several animal pilot studies, most recently in"/>
 <result pre="(OSU-03012; [24, 102]), and K11777, a protease inhibitor developed for" exact="Chagas disease," post="which has additional activity against SARS-CoV and Ebola virus"/>
 <result pre="Alphaviruses can cause a number of diseases in humans, including" exact="Chikungunya fever," post="Eastern, Western and Venezuelan equine encephalitis. The handling of"/>
 <result pre="of diseases in humans, including Chikungunya fever, Eastern, Western and" exact="Venezuelan equine encephalitis." post="The handling of the respective viruses requires BLS-3 containment."/>
 <result pre="viruses requires BLS-3 containment. Two type species, Venezuelan and Eastern" exact="Equine" post="Encephalitis viruses (VEEV and EEEV), are considered potential biological"/>
 <result pre="requires BLS-3 containment. Two type species, Venezuelan and Eastern Equine" exact="Encephalitis" post="viruses (VEEV and EEEV), are considered potential biological threat"/>
 <result pre="populations [142] and represent category B select agents. While human" exact="infections" post="with VEEV and EEEV are rare, sporadic and unpredictable"/>
 <result pre="last decade mainly in South-East Asia and in South America," exact="Central" post="America and the Caribbean, globally amounting to millions of"/>
 <result pre="Caribbean, globally amounting to millions of cases. Autochthonous cases of" exact="Chikungunya fever" post="have been reported in Italy [93]. Viremia with rashes"/>
 <result pre="fever usually lead to death of cells lining joints, causing" exact="arthritis" post="and joint pain. CHIKV infections of neurons can result"/>
 <result pre="of cells lining joints, causing arthritis and joint pain. CHIKV" exact="infections" post="of neurons can result in potentially fatal encephalitis. Fatal"/>
 <result pre="seen in human infants, are rare, but long-lasting polyarthralgia and" exact="encephalitis" post="cause significant morbidity [95]. Alphaviruses are enveloped viruses with"/>
 <result pre="viruses with positive-sense ss-RNA genomes. Most experimental antivirals target the" exact="viral" post="RNA polymerase. There are no licensed antiviral drugs against"/>
 <result pre="polymerase. There are no licensed antiviral drugs against alphaviruses causing" exact="arthritis" post="and encephalitis, and the treatment of infections is mainly"/>
 <result pre="against alphaviruses causing arthritis and encephalitis, and the treatment of" exact="infections" post="is mainly supportive (anti-inflammatory drugs, glucocorticoids). Anti-alphavirus drugs. While"/>
 <result pre="drugs. While pox- and filoviruses are highly lethal biological agents," exact="alphavirus infections" post="are rarely fatal, but can lead to large numbers"/>
 <result pre="While pox- and filoviruses are highly lethal biological agents, alphavirus" exact="infections" post="are rarely fatal, but can lead to large numbers"/>
 <result pre="encephalitis. Intravenous Ribavirin, which is FDA approved for HCV and" exact="respiratory" post="syncytial virus (RSV) infection, does not pass the BBB,"/>
 <result pre="virus (RSV) infection, does not pass the BBB, thus alleviating" exact="peripheral" post="symptoms but not providing cure [1, 3]. Intranasal ribavirin"/>
 <result pre="[1, 3]. Intranasal ribavirin may be more effective. Ribavirin resolves" exact="joint swelling" post="in CHIKV [121], but has no activity against VEEV"/>
 <result pre="are the old antiparasitic suramin, which shows ameliorating effects against" exact="CHIKV infection" post="in mice [82] and the anthelmintic ivermectin, which shows"/>
 <result pre="the old antiparasitic suramin, which shows ameliorating effects against CHIKV" exact="infection" post="in mice [82] and the anthelmintic ivermectin, which shows"/>
 <result pre="of alphaviruses [141]. Compounds with known cellular targets include the" exact="cancer" post="drugs mefenamic acid and sorafenib, inhibiting replication of CHIKV"/>
 <result pre="Arenaviruses (Lassa virus—Old World/Junin, Machupo virus—New World) can also cause" exact="viral" post="hemorrhagic fevers and are therefore on the list of"/>
 <result pre="Lassa virus (LassaV) requires BSL-4 containment. Annual case numbers of" exact="Lassa fever" post="(LassaF) are estimated to be between 100.000 and 300.000"/>
 <result pre="unknown, as are exact case numbers on New World arenavirus" exact="infections" post="[147]. Transmitted by aerosolized rodent droppings, arenavirus infections start"/>
 <result pre="World arenavirus infections [147]. Transmitted by aerosolized rodent droppings, arenavirus" exact="infections" post="start with a generalized flu-like illness and then cause"/>
 <result pre="GP2 [91]. Bunyaviridae Human pathogenic bunyaviruses, particularly Hantaviruses and Crimean-Congo" exact="Hemorrhagic" post="Fever Virus (CCHFV), can cause hemorrhagic fevers, and CCHFV"/>
 <result pre="[91]. Bunyaviridae Human pathogenic bunyaviruses, particularly Hantaviruses and Crimean-Congo Hemorrhagic" exact="Fever" post="Virus (CCHFV), can cause hemorrhagic fevers, and CCHFV is"/>
 <result pre="are dead-end hosts, suffering fatal outcomes in the case of" exact="Crimean-Congo hemorrhagic fever" post="(CCHF), as well as in hemorrhagic fever with renal"/>
 <result pre="case of Crimean-Congo hemorrhagic fever (CCHF), as well as in" exact="hemorrhagic fever with renal syndrome" post="(HFRS; Europe—South-East Asia; Puumala/Hantaan-type viruses) and hantavirus pulmonary syndrome"/>
 <result pre="fever (CCHF), as well as in hemorrhagic fever with renal" exact="syndrome" post="(HFRS; Europe—South-East Asia; Puumala/Hantaan-type viruses) and hantavirus pulmonary syndrome"/>
 <result pre="fever with renal syndrome (HFRS; Europe—South-East Asia; Puumala/Hantaan-type viruses) and" exact="hantavirus pulmonary syndrome" post="(HPS; Americas; Sin Nombre-type viruses). The clinical outcome is"/>
 <result pre="with renal syndrome (HFRS; Europe—South-East Asia; Puumala/Hantaan-type viruses) and hantavirus" exact="pulmonary" post="syndrome (HPS; Americas; Sin Nombre-type viruses). The clinical outcome"/>
 <result pre="renal syndrome (HFRS; Europe—South-East Asia; Puumala/Hantaan-type viruses) and hantavirus pulmonary" exact="syndrome" post="(HPS; Americas; Sin Nombre-type viruses). The clinical outcome is"/>
 <result pre="[17, 76, 127] as reported by the European Center for" exact="Disease" post="Control [38]. Bunyavirus infections are endemic, vector-borne infections. Normally"/>
 <result pre="reported by the European Center for Disease Control [38]. Bunyavirus" exact="infections" post="are endemic, vector-borne infections. Normally they do not cause"/>
 <result pre="illness and fever which lasts for about 3 days, these" exact="infections" post="can end in fatal hemorrhagic fever (CCHF, HFRS), and"/>
 <result pre="infections can end in fatal hemorrhagic fever (CCHF, HFRS), and" exact="pulmonary" post="syndrome (HPS) with a 1–40% case fatality rate depending"/>
 <result pre="can end in fatal hemorrhagic fever (CCHF, HFRS), and pulmonary" exact="syndrome" post="(HPS) with a 1–40% case fatality rate depending on"/>
 <result pre="against a number of phleboviruses (PhleboV) and to treat CCHFV" exact="infection" post="in rodent models [53, 54, 59], galidesivir (BCX4430), effective"/>
 <result pre="in rodent models [53, 54, 59], galidesivir (BCX4430), effective against" exact="Rift Valley fever" post="virus (RVFV) infection in a hamster model and investigated"/>
 <result pre="59], galidesivir (BCX4430), effective against Rift Valley fever virus (RVFV)" exact="infection" post="in a hamster model and investigated for use by"/>
 <result pre="the FDA [145], 2′-fluoro-2′-deoxycytidine (2FdC), which showed protective effects against" exact="infections" post="with PhleboV in a rodent model [134], and the"/>
 <result pre="entry inhibitor [135]. Flaviviridae Flaviviruses causing hemorrhagic fever or severe" exact="encephalitis" post="(Omsk hemorrhagic fever, Dengue and Yellow fever, Russian spring–summer"/>
 <result pre="Flaviviruses causing hemorrhagic fever or severe encephalitis (Omsk hemorrhagic fever," exact="Dengue" post="and Yellow fever, Russian spring–summer encephalitis/Tick Borne Encephalitis (TBEV))"/>
 <result pre="hemorrhagic fever or severe encephalitis (Omsk hemorrhagic fever, Dengue and" exact="Yellow fever," post="Russian spring–summer encephalitis/Tick Borne Encephalitis (TBEV)) are listed as"/>
 <result pre="or severe encephalitis (Omsk hemorrhagic fever, Dengue and Yellow fever," exact="Russian" post="spring–summer encephalitis/Tick Borne Encephalitis (TBEV)) are listed as potential"/>
 <result pre="hemorrhagic fever, Dengue and Yellow fever, Russian spring–summer encephalitis/Tick Borne" exact="Encephalitis" post="(TBEV)) are listed as potential biological threat agents (NATO"/>
 <result pre="distributions, causing regular outbreaks and fatalities, with 30.000 cases/year through" exact="yellow fever" post="in Africa alone [51, 149]. Infections with flaviviruses can"/>
 <result pre="30.000 cases/year through yellow fever in Africa alone [51, 149]." exact="Infections" post="with flaviviruses can lead to hemorrhagic fevers (Omsk hemorrhagic"/>
 <result pre="with flaviviruses can lead to hemorrhagic fevers (Omsk hemorrhagic fever," exact="yellow fever" post="(YF) and dengue fever with case fatality rates of"/>
 <result pre="to hemorrhagic fevers (Omsk hemorrhagic fever, yellow fever (YF) and" exact="dengue fever" post="with case fatality rates of up to 30%) or"/>
 <result pre="rates of up to 30%) or affect the CNS, causing" exact="encephalitis" post="(e.g., Japanese encephalitis, tick borne encephalitis with case fatality"/>
 <result pre="up to 30%) or affect the CNS, causing encephalitis (e.g.," exact="Japanese encephalitis," post="tick borne encephalitis with case fatality rates up to"/>
 <result pre="affect the CNS, causing encephalitis (e.g., Japanese encephalitis, tick borne" exact="encephalitis" post="with case fatality rates up to 20%, Zika and"/>
 <result pre="Nile encephalitis). Human-to-human transmission is not effective. Live vaccines against" exact="yellow fever" post="(17D) and Japanese Encephalitis (JE), a number of inactivated"/>
 <result pre="is not effective. Live vaccines against yellow fever (17D) and" exact="Japanese Encephalitis" post="(JE), a number of inactivated TBEV vaccines, and most"/>
 <result pre="not effective. Live vaccines against yellow fever (17D) and Japanese" exact="Encephalitis" post="(JE), a number of inactivated TBEV vaccines, and most"/>
 <result pre="number of inactivated TBEV vaccines, and most recently a live" exact="Dengue" post="virus vaccine are available. Flaviviruses are a large family"/>
 <result pre="[42]. Anti-flavivirus drugs. Ribavirin is an effective early treatment for" exact="yellow fever" post="under compassionate use protocols, but fails to improve survival"/>
 <result pre="compassionate use protocols, but fails to improve survival of dengue" exact="infections" post="in non-human primates (NHP; [92, 103]. Out of a"/>
 <result pre="was initially developed and approved by FDA for treatment of" exact="hepatitis" post="C. It shows activity against a number of flaviviruses"/>
 <result pre="interesting candidates (13 compounds listed in Table 1) inhibit the" exact="viral" post="polymerase [39, 128]), NS2B/NS3 protease and kinases [23, 24]),"/>
 <result pre="so far tested in animal models for the treatment of" exact="infections" post="with Usutu (UsutuV), Dengue (DENV) and Zika viruses (ZikaV)"/>
 <result pre="animal models for the treatment of infections with Usutu (UsutuV)," exact="Dengue" post="(DENV) and Zika viruses (ZikaV) is their rather low"/>
 <result pre="could be considered as potential biological threat agents. Handling of" exact="avian influenza" post="viruses and other influenza viruses with high pathogenic potential"/>
 <result pre="with high pathogenic potential requires BSL-3 containment. Pandemic influenza viruses" exact="type A" post="are transmitted by the respiratory route to birds and"/>
 <result pre="containment. Pandemic influenza viruses type A are transmitted by the" exact="respiratory" post="route to birds and mammals, type B only from"/>
 <result pre="are transmitted by the respiratory route to birds and mammals," exact="type B" post="only from human to human, as well as via"/>
 <result pre="well as via saliva, nasal secretions, feces and blood, causing" exact="acute" post="respiratory distress with potentially fatal outcomes in humans. In"/>
 <result pre="as via saliva, nasal secretions, feces and blood, causing acute" exact="respiratory" post="distress with potentially fatal outcomes in humans. In humans,"/>
 <result pre="respiratory distress with potentially fatal outcomes in humans. In humans," exact="infection" post="of the respiratory tract can lead to pneumonia, secondary"/>
 <result pre="potentially fatal outcomes in humans. In humans, infection of the" exact="respiratory" post="tract can lead to pneumonia, secondary pneumonia and overwhelming"/>
 <result pre="humans, infection of the respiratory tract can lead to pneumonia," exact="secondary" post="pneumonia and overwhelming immune responses, followed by multiorgan failure"/>
 <result pre="infection of the respiratory tract can lead to pneumonia, secondary" exact="pneumonia" post="and overwhelming immune responses, followed by multiorgan failure in"/>
 <result pre="are enveloped viruses with a negative-sense segmented ss-RNA genome. The" exact="viral" post="RNA polymerase has a high error rate of 1/10,000."/>
 <result pre="only when given early but may be useful in severe" exact="infections" post="requiring hospitalization/mechanical ventilation [57]. In 2018 baloxavir-marboxil (Xofluza®), an"/>
 <result pre="ventilation [57]. In 2018 baloxavir-marboxil (Xofluza®), an inhibitor of the" exact="viral" post="cap-dependent endonuclease (CEN; influenza virus polymerase PA subunit), was"/>
 <result pre="to inhibit influenza virus hemagglutinin maturation and intracellular trafficking of" exact="viral" post="components in infected cells and that are now in"/>
 <result pre="described in 1985 as M2 protein blockers ([60]; H + channel/viroporin; only" exact="type A" post="viruses), are not recommended anymore for clinical use (WHO/US),"/>
 <result pre="anymore for clinical use (WHO/US), due to rapid induction of" exact="viral" post="resistance mutations: 100% of clinical isolates are resistant. A"/>
 <result pre="real concern in the veterinary and biodefense communities about spill-over" exact="infections" post="and the high fatality rate in humans (632 human"/>
 <result pre="are canine distemper virus (CDV), endemic in Europe (dogs/humans; [11])," exact="Newcastle disease" post="virus affecting birds, and rinderpest virus infecting cattle. Human"/>
 <result pre="canine distemper virus (CDV), endemic in Europe (dogs/humans; [11]), Newcastle" exact="disease" post="virus affecting birds, and rinderpest virus infecting cattle. Human"/>
 <result pre="birds, and rinderpest virus infecting cattle. Human parainfluenza viruses and" exact="respiratory" post="syncytial virus (RSV) are major causes of bronchiolitis, bronchitis"/>
 <result pre="and respiratory syncytial virus (RSV) are major causes of bronchiolitis," exact="bronchitis" post="and pneumonia in infants and children. Measles (morbilli, rubeola)"/>
 <result pre="syncytial virus (RSV) are major causes of bronchiolitis, bronchitis and" exact="pneumonia" post="in infants and children. Measles (morbilli, rubeola) caused by"/>
 <result pre="pneumonia in infants and children. Measles (morbilli, rubeola) caused by" exact="measles" post="virus (MeaslesV) was responsible for around 733,000 deaths globally"/>
 <result pre="around 733,000 deaths globally in 2000 [22], mostly due to" exact="viral pneumonia," post="secondary bacterial infections due to immune suppression (B cell"/>
 <result pre="deaths globally in 2000 [22], mostly due to viral pneumonia," exact="secondary" post="bacterial infections due to immune suppression (B cell tropism),"/>
 <result pre="globally in 2000 [22], mostly due to viral pneumonia, secondary" exact="bacterial infections" post="due to immune suppression (B cell tropism), and encephalitides"/>
 <result pre="in 2000 [22], mostly due to viral pneumonia, secondary bacterial" exact="infections" post="due to immune suppression (B cell tropism), and encephalitides"/>
 <result pre="to immune suppression (B cell tropism), and encephalitides [inclusion body" exact="encephalitis" post="(MIBE); subacute sclerosing panencephalitis (SSPE)]. A very successful vaccine"/>
 <result pre="suppression (B cell tropism), and encephalitides [inclusion body encephalitis (MIBE);" exact="subacute sclerosing panencephalitis" post="(SSPE)]. A very successful vaccine (MeaslesV strain Edmonston) has"/>
 <result pre="strain Edmonston) has been used with the goal to eradicate" exact="measles" post="in 2010 [62]. However, anti-vaccine movements have led to"/>
 <result pre="to the loss of herd immunity and the reemergence of" exact="measles" post="in many developed countries [28, 46]. Paramyxoviruses are a"/>
 <result pre="been shown to be effective in a mouse model for" exact="measles" post="encephalitis [69]. A very promising candidate antiviral against measles"/>
 <result pre="shown to be effective in a mouse model for measles" exact="encephalitis" post="[69]. A very promising candidate antiviral against measles is"/>
 <result pre="for measles encephalitis [69]. A very promising candidate antiviral against" exact="measles" post="is ERDRP-0519, which has been shown effective against canine"/>
 <result pre="described [74]. Favipiravir has a protective effect against Nipah virus" exact="infections" post="in the hamster model [29], and remdesivir inhibits a"/>
 <result pre="vitro [63], but showed low efficacy and high toxicity in" exact="hepatitis" post="C patients in early clinical trials [108]. Synergy through"/>
 <result pre="efficacy and, by means of individual dose reduction, allow for" exact="lower" post="toxicity of the individual compounds. This exploits possible synergies"/>
 <result pre="pointed out by many authors, including in the context of" exact="yellow fever" post="treatment [103]. Examples for synergistic effects in combinations of"/>
 <result pre="similar or different MoA are ribavirin with vitamin A in" exact="measles" post="infections [12], ribavirin with favipiravir in Zika virus infections"/>
 <result pre="or different MoA are ribavirin with vitamin A in measles" exact="infections" post="[12], ribavirin with favipiravir in Zika virus infections [75],"/>
 <result pre="in measles infections [12], ribavirin with favipiravir in Zika virus" exact="infections" post="[75], and ribavirin with mefenamic acid in infections with"/>
 <result pre="Zika virus infections [75], and ribavirin with mefenamic acid in" exact="infections" post="with Chikungunya virus [126]. Antiviral drug combinations may also"/>
 <result pre="or distinct virus families, allowing the empirical treatment of severe" exact="viral" post="infections prior to positive diagnosis of the viral agent."/>
 <result pre="distinct virus families, allowing the empirical treatment of severe viral" exact="infections" post="prior to positive diagnosis of the viral agent. Leading"/>
 <result pre="of severe viral infections prior to positive diagnosis of the" exact="viral" post="agent. Leading examples are at his point the pyrazine-carboxamide"/>
 <result pre="(favipiravir; [2, 7, 48]), T-1105 and T-1106, which are broad-spectrum" exact="viral" post="RNA polymerase inhibitors, initially developed for the treatment of"/>
 <result pre="viruses in vitro, including Borna virus, HCV, Lassa virus, certain" exact="herpes" post="viruses, and which also inhibits influenza viruses in mice"/>
 <result pre="active compound cannot be identified in extracts [27]. Treatment of" exact="viral" post="hemorrhagic fevers (VHF) with ribavirin Viral hemorrhagic fevers (VHFs)"/>
 <result pre="extracts [27]. Treatment of viral hemorrhagic fevers (VHF) with ribavirin" exact="Viral" post="hemorrhagic fevers (VHFs) cause the highest mortality in human"/>
 <result pre="cause the highest mortality in human hosts of all known" exact="viral" post="agents and treatment options are a serious concern both"/>
 <result pre="the mainstay of clinical interventions in VHF, including hemodynamic, hematological," exact="pulmonary" post="and neurological support treatments. Treatment with corticosteroids, vasoactive substances,"/>
 <result pre="hemodialysis and both morbidity and mortality in the case of" exact="Lassa fever" post="(LassaF). Ribavirin (Copegus™, Rebetol™, Virazole® ICN/Valeant (IND)) is used"/>
 <result pre="Rebetol™, Virazole® ICN/Valeant (IND)) is used for the treatment of" exact="infections" post="with African arenaviruses (Lujo- and Lassa fever) and bunyaviruses"/>
 <result pre="ICN/Valeant (IND)) is used for the treatment of infections with" exact="African" post="arenaviruses (Lujo- and Lassa fever) and bunyaviruses (HFRS, Crimean-Congo"/>
 <result pre="of any of the VHFs caused by filoviruses, or in" exact="infections" post="with RNA viruses causing severe encephalitis [15, 67]. Conclusion"/>
 <result pre="by filoviruses, or in infections with RNA viruses causing severe" exact="encephalitis" post="[15, 67]. Conclusion Antiviral drug development is determined by"/>
 <result pre="determined by the virus life cycle, both the steps of" exact="viral" post="replication per se and the cellular processes supporting viral"/>
 <result pre="of viral replication per se and the cellular processes supporting" exact="viral" post="replication. The action of antivirals targeting a viral replication"/>
 <result pre="processes supporting viral replication. The action of antivirals targeting a" exact="viral" post="replication step may be augmented by an antiviral hitting"/>
 <result pre="step may be augmented by an antiviral hitting a different" exact="viral" post="target or a cell process, or secondary effects via"/>
 <result pre="hitting a different viral target or a cell process, or" exact="secondary" post="effects via drug metabolism, resulting in synergy. Most antivirals"/>
 <result pre="via testing in single cell types (organotypic cell lines or" exact="primary" post="cells) to determine IC50/CC50 = SI, and complex infection models to"/>
 <result pre="cell lines or primary cells) to determine IC50/CC50 = SI, and complex" exact="infection" post="models to animal models, clinical trials, and eventually regulatory"/>
 <result pre="for lack of interest and funding. Human organoids/complex in vitro" exact="infection" post="models (e.g., barrier models) may provide a bridge to"/>
 <result pre="even the threat of a biological attack would cause mass" exact="hysteria" post="with concomitant economic disruption. Only timely preparation underlined by"/>
 <result pre="of the respective publishing journals. References References 1.AbdelnabiRNeytsJDelangLTowards antivirals against" exact="chikungunya" post="virusAntivir Res2015121596810.1016/j.antiviral.2015.06.01726119058 2.AbdelnabiRde MoraisATSLeyssenPImbertIBeaucourtSBlancHFroeyenMVignuzziMCanardBNeytsJDelangLUnderstanding the mechanism of the broad-spectrum"/>
 <result pre="favipiravir (T-705): key role of the F1 motif of the" exact="viral" post="polymeraseJ Virol201710.1128/JVI.00487-1728381577 3.AbdelnabiRJochmansDVerbekenENeytsJDelangLAntiviral treatment efficiently inhibits chikungunya virus infection"/>
 <result pre="motif of the viral polymeraseJ Virol201710.1128/JVI.00487-1728381577 3.AbdelnabiRJochmansDVerbekenENeytsJDelangLAntiviral treatment efficiently inhibits" exact="chikungunya" post="virus infection in the joints of mice during the"/>
 <result pre="of the viral polymeraseJ Virol201710.1128/JVI.00487-1728381577 3.AbdelnabiRJochmansDVerbekenENeytsJDelangLAntiviral treatment efficiently inhibits chikungunya" exact="virus infection" post="in the joints of mice during the acute but"/>
 <result pre="the viral polymeraseJ Virol201710.1128/JVI.00487-1728381577 3.AbdelnabiRJochmansDVerbekenENeytsJDelangLAntiviral treatment efficiently inhibits chikungunya virus" exact="infection" post="in the joints of mice during the acute but"/>
 <result pre="chikungunya virus infection in the joints of mice during the" exact="acute" post="but not during the chronic phase of the infectionAntivir"/>
 <result pre="joints of mice during the acute but not during the" exact="chronic" post="phase of the infectionAntivir Res201814911311710.1016/j.antiviral.2017.09.01628958920 4.AhmedASiman-TovGKeckFKortchakSBakovicARisnerKLuTKBhallaNde la Fuente-NunezCNarayananAHuman cathelicidin"/>
 <result pre="la Fuente-NunezCNarayananAHuman cathelicidin peptide LL-37 as a therapeutic antiviral targeting" exact="Venezuelan equine encephalitis" post="virus infectionsAntivir Res2019164616910.1016/j.antiviral.2019.02.00230738837 5.AltmannSESmithALDyallJJohnsonRFDoddLEJahrlingPBParagasJBlaneyJEInhibition of cowpox virus and monkeypox"/>
 <result pre="cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine" exact="encephalitis" post="virus infectionsAntivir Res2019164616910.1016/j.antiviral.2019.02.00230738837 5.AltmannSESmithALDyallJJohnsonRFDoddLEJahrlingPBParagasJBlaneyJEInhibition of cowpox virus and monkeypox"/>
 <result pre="antiviral targeting Venezuelan equine encephalitis virus infectionsAntivir Res2019164616910.1016/j.antiviral.2019.02.00230738837 5.AltmannSESmithALDyallJJohnsonRFDoddLEJahrlingPBParagasJBlaneyJEInhibition of" exact="cowpox" post="virus and monkeypox virus infection by mitoxantroneAntivir Res20129330530810.1016/j.antiviral.2011.12.00122182595 6.Alves"/>
 <result pre="equine encephalitis virus infectionsAntivir Res2019164616910.1016/j.antiviral.2019.02.00230738837 5.AltmannSESmithALDyallJJohnsonRFDoddLEJahrlingPBParagasJBlaneyJEInhibition of cowpox virus and" exact="monkeypox" post="virus infection by mitoxantroneAntivir Res20129330530810.1016/j.antiviral.2011.12.00122182595 6.Alves GalvãoMGRocha Crispino SantosMAAlves"/>
 <result pre="encephalitis virus infectionsAntivir Res2019164616910.1016/j.antiviral.2019.02.00230738837 5.AltmannSESmithALDyallJJohnsonRFDoddLEJahrlingPBParagasJBlaneyJEInhibition of cowpox virus and monkeypox" exact="virus infection" post="by mitoxantroneAntivir Res20129330530810.1016/j.antiviral.2011.12.00122182595 6.Alves GalvãoMGRocha Crispino SantosMAAlves da CunhaAJAmantadine"/>
 <result pre="virus infectionsAntivir Res2019164616910.1016/j.antiviral.2019.02.00230738837 5.AltmannSESmithALDyallJJohnsonRFDoddLEJahrlingPBParagasJBlaneyJEInhibition of cowpox virus and monkeypox virus" exact="infection" post="by mitoxantroneAntivir Res20129330530810.1016/j.antiviral.2011.12.00122182595 6.Alves GalvãoMGRocha Crispino SantosMAAlves da CunhaAJAmantadine"/>
 <result pre="novel series of compounds with selective 616 antiviral activity against" exact="chikungunya" post="virusAntivir Res201398121810.1016/j.antiviral.2013.01.00223380636 10.BazMCarbonneauJRhéaumeCCavanaghM-HBoivinGCombination therapy with oseltamivir and favipiravir delays"/>
 <result pre="deadly virus approvedNature-News201910.1038/d41586-019-03490-8 20.CannalireRTarantinoDPiorkowskiGCarlettiTMassariSFelicettiTBarrecaMLSabatiniSTabarriniOMarcelloAMilaniMCecchettiVMastrangeloEManfroniGQueratGBroad spectrum anti-flavivirus pyridobenzothiazolones leading to less" exact="infective" post="virionsAntivir Res201916761210.1016/j.antiviral.2019.03.00430849420 21.CarolineALPowellDSBethelLMOuryTDReedDSHartmanALBroad spectrum antiviral activity of favipiravir (T-705):"/>
 <result pre="lethal inhalational rift valley feverPLoS Negl Trop Dis20148e279010.1371/journal.pntd.000279024722586 22.collab: CDCGlobal" exact="measles" post="mortality, 2000–2008MMWR2009581321132619959985 23.ChanJF-WChikKK-HYuanSYipCC-YZhuZTeeK-MTsangJO-LChanCC-SPoonVK-MLuGZhangAJLaiK-KChanK-HKaoRY-TYuenK-YNovel antiviral activity and mechanism of bromocriptine"/>
 <result pre="identification of compounds from Kalanchoe pinnata having human alphaherpesvirus and" exact="vaccinia" post="virus antiviral activityPharm Biol2017551586159110.1080/13880209.2017.131090728395583 28.Dahl (1986) MEASLES: a dangerous"/>
 <result pre="(1986) MEASLES: a dangerous illness. https://www.encephalitis.info/Handlers/Download.ashx?IDMF=9ea058b7-fd6f-493e-8589-34d56e9ac164 29.DawesBEKalveramBIkegamiTJuelichTSmithJKZhangLParkALeeBKomenoTFurutaYFreibergANFavipiravir (T-705) protects against" exact="Nipah virus infection" post="in the hamster modelSci Rep20188760410.1038/s41598-018-25780-329765101 30.De BurghgraeveTSeliskoBKapteinSChatelainGLeyssenPDebingYJacobsMVan AerschotACanardBNeytsJ3′,5′Di-O-trityluridine inhibits"/>
 <result pre="MEASLES: a dangerous illness. https://www.encephalitis.info/Handlers/Download.ashx?IDMF=9ea058b7-fd6f-493e-8589-34d56e9ac164 29.DawesBEKalveramBIkegamiTJuelichTSmithJKZhangLParkALeeBKomenoTFurutaYFreibergANFavipiravir (T-705) protects against Nipah" exact="virus infection" post="in the hamster modelSci Rep20188760410.1038/s41598-018-25780-329765101 30.De BurghgraeveTSeliskoBKapteinSChatelainGLeyssenPDebingYJacobsMVan AerschotACanardBNeytsJ3′,5′Di-O-trityluridine inhibits"/>
 <result pre="a dangerous illness. https://www.encephalitis.info/Handlers/Download.ashx?IDMF=9ea058b7-fd6f-493e-8589-34d56e9ac164 29.DawesBEKalveramBIkegamiTJuelichTSmithJKZhangLParkALeeBKomenoTFurutaYFreibergANFavipiravir (T-705) protects against Nipah virus" exact="infection" post="in the hamster modelSci Rep20188760410.1038/s41598-018-25780-329765101 30.De BurghgraeveTSeliskoBKapteinSChatelainGLeyssenPDebingYJacobsMVan AerschotACanardBNeytsJ3′,5′Di-O-trityluridine inhibits"/>
 <result pre="passes 2000 cases amid violence and suspicionBMJ2019365l406210.1136/bmj.l406231167752 38.European Center for" exact="Disease" post="Control (ECDC) (2016) Hantavirus infection—Annual Epidemiological Report for 2016."/>
 <result pre="of the adenosine analogue BCX4430 against West Nile virus and" exact="tick-borne" post="flavivirusesAntivir Res2017142636710.1016/j.antiviral.2017.03.01228336346 40.FerreiraACReisPAde FreitasCSSacramentoCQVillas Bôas HoelzLBastosMMMattosMRochaNGomes de Azevedo QuintanilhaIda"/>
 <result pre="Faria NetoHCBoechatNRehenSKBrüningKBozzaFABozzaPTSouzaTMLBeyond members of the Flaviviridae family, Sofosbuvir also inhibits" exact="chikungunya" post="virus replicationAntimicrob Agents Chemother201910.1128/AAC.01389-1831844010 41.Ferreira-RamosASLiCEydouxCContrerasJMMoriceCQuératGGiganteAPérez PérezM-JJungM-LCanardBGuillemotJ-CDecrolyECoutardBApproved drugs screening against"/>
 <result pre="41.Ferreira-RamosASLiCEydouxCContrerasJMMoriceCQuératGGiganteAPérez PérezM-JJungM-LCanardBGuillemotJ-CDecrolyECoutardBApproved drugs screening against the nsP1 capping enzyme of" exact="Venezuelan equine encephalitis" post="virus using an immuno-based assayAntivir Res2019163596910.1016/j.antiviral.2019.01.00330639438 42.FieldsBNKnipeDMHowleyPMFields virology20136PhiladelphiaWolters Kluwer"/>
 <result pre="drugs screening against the nsP1 capping enzyme of Venezuelan equine" exact="encephalitis" post="virus using an immuno-based assayAntivir Res2019163596910.1016/j.antiviral.2019.01.00330639438 42.FieldsBNKnipeDMHowleyPMFields virology20136PhiladelphiaWolters Kluwer"/>
 <result pre="Virol2012862729273810.1128/JVI.05591-1122190718 44.FosterSAParkerSLanierRThe role of brincidofovir in preparation for a potential" exact="smallpox" post="outbreakViruses201710.3390/v911032029773767 45.FrancoEJRodriquezJLPomeroyJJHanrahanKCBrownANThe effectiveness of antiviral agents with broad-spectrum activity"/>
 <result pre="outbreakViruses201710.3390/v911032029773767 45.FrancoEJRodriquezJLPomeroyJJHanrahanKCBrownANThe effectiveness of antiviral agents with broad-spectrum activity against" exact="chikungunya" post="virus varies between host cell linesAntivir Chem Chemother201826204020661880758010.1177/204020661880758030354193 46.Fraser-bellCJGlobal"/>
 <result pre="varies between host cell linesAntivir Chem Chemother201826204020661880758010.1177/204020661880758030354193 46.Fraser-bellCJGlobal re-emergence of" exact="measles" post="updateGlob Biosecur201910.31646/gbio.43 47.FreestoneDSThe need for new antiviral agentsAntivir Res1985530732410.1016/0166-3542(85)90001-43004326"/>
 <result pre="T-705Antimicrob Agents Chemother20024697798110.1128/AAC.46.4.977-981.200211897578 49.FurutaYKomenoTNakamuraTFavipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Jpn Acad Ser B20179344946310.2183/pjab.93.02728769016 50.García-NicolásOV’kovskiPVielleNJEbertNZüstRPortmannJStalderHGaschenVVieyresGStoffelMSchweizerMSummerfieldAEnglerOPietschmannTTodtDAlvesMPThielVPfaenderSThe small-compound inhibitor"/>
 <result pre="offers potential as a panviral inhibitorAntimicrob Agents Chemother201810.1128/AAC.01206-1830181371 51.GarskeTVan KerkhoveMDYactayoSRonveauxOLewisRFStaplesJEPereaWFergusonNMCommitteeYellow" exact="Fever" post="ExpertYellow fever in Africa: estimating the burden of disease"/>
 <result pre="KerkhoveMDYactayoSRonveauxOLewisRFStaplesJEPereaWFergusonNMCommitteeYellow Fever ExpertYellow fever in Africa: estimating the burden of" exact="disease" post="and impact of mass vaccination from outbreak and serological"/>
 <result pre="to favipiravir in influenzaPNAS2018115116131161810.1073/pnas.181134511530352857 53.GowenBBHolbrookMRAnimal models of highly pathogenic RNA" exact="viral" post="infections: hemorrhagic fever virusesAntivir Res200878799010.1016/j.antiviral.2007.10.00218036672 54.GowenBBWongM-HJungK-HSmeeDFMorreyJDFurutaYEfficacy of favipiravir (T-705)"/>
 <result pre="54.GowenBBWongM-HJungK-HSmeeDFMorreyJDFurutaYEfficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus" exact="disease" post="modelsAntivir Res20108612112710.1016/j.antiviral.2009.10.01519874853 55.GrosenbachDWHoneychurchKRoseEAChinsangaramJFrimmAMaitiBLovejoyCMearaILongPHrubyDEOral tecovirimat for the treatment of smallpoxN"/>
 <result pre="but not ribavirin is effective against two distinct strains of" exact="Crimean-Congo hemorrhagic fever" post="virus in miceAntivir Res2018157182610.1016/j.antiviral.2018.06.01329936152 60.HayAJWolstenholmeAJSkehelJJSmithMHThe molecular basis of the"/>
 <result pre="lethal mouse modelJ Infect Dis1999179Suppl 1S240S24710.1086/5143169988190 65.HugginsJWProspects for treatment of" exact="viral" post="hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drugRev Infect"/>
 <result pre="4S750S76110.1093/clinids/11.Supplement_4.S7502546248 66.HwangJJiangAFikrigEA potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and" exact="Dengue" post="virusesAntivir Res201916116316810.1016/j.antiviral.2018.11.01730521835 67.IppolitoGFeldmannHLaniniSVairoFDi CaroACapobianchiMRNicastriEViral hemorrhagic fevers: advancing the level"/>
 <result pre="brain using cyclodextrin as a drug carrier: evaluation in a" exact="measles" post="encephalitis modelAntivir Res20098126126610.1016/j.antiviral.2008.12.00619133295 70.JohnsonSHenschkeNMaayanNMillsIBuckleyBSKakourouAMarshallRRibavirin for treating Crimean Congo haemorrhagic"/>
 <result pre="using cyclodextrin as a drug carrier: evaluation in a measles" exact="encephalitis" post="modelAntivir Res20098126126610.1016/j.antiviral.2008.12.00619133295 70.JohnsonSHenschkeNMaayanNMillsIBuckleyBSKakourouAMarshallRRibavirin for treating Crimean Congo haemorrhagic feverCochrane"/>
 <result pre="Crimean Congo haemorrhagic feverCochrane Database Syst Rev201810.1002/14651858.CD012713.pub230362116 71.JonssonCBHooperJMertzGTreatment of hantavirus" exact="pulmonary" post="syndromeAntivir Res20087816216910.1016/j.antiviral.2007.10.01218093668 72.JonssonCBCaoXLeeJGabbardJDChuY-KFitzpatrickEAJulanderJChungD-HStabenowJGoldenJEEfficacy of a ML336 derivative against Venezuelan"/>
 <result pre="syndromeAntivir Res20087816216910.1016/j.antiviral.2007.10.01218093668 72.JonssonCBCaoXLeeJGabbardJDChuY-KFitzpatrickEAJulanderJChungD-HStabenowJGoldenJEEfficacy of a ML336 derivative against Venezuelan and" exact="eastern equine encephalitis" post="virusesAntivir Res2019167253410.1016/j.antiviral.2019.04.00430970271 73.KachkoACostafredaMIZubkovaIJacquesJTakedaKWellsFKaplanGMajorMEDeterminants in the Ig variable domain of"/>
 <result pre="72.JonssonCBCaoXLeeJGabbardJDChuY-KFitzpatrickEAJulanderJChungD-HStabenowJGoldenJEEfficacy of a ML336 derivative against Venezuelan and eastern equine" exact="encephalitis" post="virusesAntivir Res2019167253410.1016/j.antiviral.2019.04.00430970271 73.KachkoACostafredaMIZubkovaIJacquesJTakedaKWellsFKaplanGMajorMEDeterminants in the Ig variable domain of"/>
 <result pre="variable domain of human HAVCR1 (TIM-1) are required to enhance" exact="hepatitis" post="C virus entryJ Virol2018159210.1128/jvi.01742-17 74.KalbermatterDShresthaNAder-EbertNHerrenMMollPPlemperRKAltmannK-HLangedijkJPGallFLindenmannURiedlRFotiadisDPlattetPPrimary resistance mechanism of the"/>
 <result pre="inhibitorVirus Res2019259283710.1016/j.virusres.2018.10.00330296457 75.KimJ-ASeongR-KKumarMShinOSFavipiravir and ribavirin inhibit replication of Asian and" exact="African" post="strains of Zika virus in different cell modelsViruses201810.3390/v1002007230463206 76.KlempaBMeiselHRäthSBartelJUlrichRKrügerDHOccurrence"/>
 <result pre="Zika virus in different cell modelsViruses201810.3390/v1002007230463206 76.KlempaBMeiselHRäthSBartelJUlrichRKrügerDHOccurrence of renal and" exact="pulmonary" post="syndrome in a region of northeast Germany where Tula"/>
 <result pre="virus in different cell modelsViruses201810.3390/v1002007230463206 76.KlempaBMeiselHRäthSBartelJUlrichRKrügerDHOccurrence of renal and pulmonary" exact="syndrome" post="in a region of northeast Germany where Tula hantavirus"/>
 <result pre="novel three-dimensional cell culture method enhances antiviral drug screening in" exact="primary" post="human cellsAntivir Res2018150202910.1016/j.antiviral.2017.12.00529224735 78.KoksalIYilmazGAksoyFAydinHYavuzIIskenderSAkcayKErensoySCaylanRAydinKThe efficacy of ribavirin in the"/>
 <result pre="cellsAntivir Res2018150202910.1016/j.antiviral.2017.12.00529224735 78.KoksalIYilmazGAksoyFAydinHYavuzIIskenderSAkcayKErensoySCaylanRAydinKThe efficacy of ribavirin in the treatment of" exact="Crimean-Congo hemorrhagic fever" post="in Eastern Black Sea region in TurkeyJ Clin Virol201047656810.1016/j.jcv.2009.11.00719962342"/>
 <result pre="available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus" exact="infection" post="in a large animal modelSci Transl Med20146232ra5210.1126/scitranslmed.300851724739760 82.KuoS-CWangY-MHoY-JChangT-YLaiZ-ZTsuiP-YWuT-YLinC-CSuramin treatment"/>
 <result pre="in a large animal modelSci Transl Med20146232ra5210.1126/scitranslmed.300851724739760 82.KuoS-CWangY-MHoY-JChangT-YLaiZ-ZTsuiP-YWuT-YLinC-CSuramin treatment reduces" exact="chikungunya" post="pathogenesis in miceAntivir Res2016134899610.1016/j.antiviral.2016.07.02527577529 83.La FraziaSPiacentiniSRiccioARossignolJ-FSantoroMGThe second-generation thiazolide haloxanide"/>
 <result pre="83.La FraziaSPiacentiniSRiccioARossignolJ-FSantoroMGThe second-generation thiazolide haloxanide is a potent inhibitor of" exact="avian influenza" post="virus replicationAntivir Res201815715916810.1016/j.antiviral.2018.06.00829908209 84.LamS-KNipah virus—a potential agent of bioterrorism?Antivir"/>
 <result pre="NS2B-NS3 proteaseAntivir Res2018201815021722510.1016/j.antiviral.2017.12.018 87.LieberherrCZhangGGrafenASingethanKKendlSVogtVMaierJBringmannGSchneider-SchauliesJThe plant-derived naphthoquinone droserone inhibits in vitro" exact="measles" post="virus infectionPlanta Med20178323223810.1055/s-0042-11182527420351 88.LoMKJordanRArveyASudhamsuJShrivastava-RanjanPHotardALFlintMMcMullanLKSiegelDClarkeMOMackmanRLHuiHCPerronMRayASCihlarTNicholSTSpiropoulouCFGS-5734 and its parent nucleoside analog"/>
 <result pre="Nipah virusAntivir Res2013100384310.1016/j.antiviral.2013.07.01123911335 90.LundbergLBrahmsAHooperICareyBLinS-CDahalBNarayananAKehn-HallKRepurposed FDA-Approved drug sorafenib reduces replication of" exact="Venezuelan equine encephalitis" post="virus and other alphavirusesAntivir Res2018157576710.1016/j.antiviral.2018.07.00529981794 91.MaduIGFilesMGharaibehDNMooreALJungK-HGowenBBDaiDJonesKFTyavanagimattSRBurgesonJRKorthMJBedardKMIadonatoSPAmbergSMA potent Lassa virus"/>
 <result pre="Res2013100384310.1016/j.antiviral.2013.07.01123911335 90.LundbergLBrahmsAHooperICareyBLinS-CDahalBNarayananAKehn-HallKRepurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine" exact="encephalitis" post="virus and other alphavirusesAntivir Res2018157576710.1016/j.antiviral.2018.07.00529981794 91.MaduIGFilesMGharaibehDNMooreALJungK-HGowenBBDaiDJonesKFTyavanagimattSRBurgesonJRKorthMJBedardKMIadonatoSPAmbergSMA potent Lassa virus"/>
 <result pre="an arenavirus virulence determinantPLoS Pathog201814e100743910.1371/journal.ppat.100743930576397 92.MalinoskiFJHastySEUsseryMADalrympleJMProphylactic ribavirin treatment of dengue" exact="type 1" post="infection in rhesus monkeysAntivir Res19901313914910.1016/0166-3542(90)90029-72353804 93.MaranoGPupellaSPatiIMasielloFFranchiniMVaglioSVelatiCLiumbrunoGMTen years since the"/>
 <result pre="virulence determinantPLoS Pathog201814e100743910.1371/journal.ppat.100743930576397 92.MalinoskiFJHastySEUsseryMADalrympleJMProphylactic ribavirin treatment of dengue type 1" exact="infection" post="in rhesus monkeysAntivir Res19901313914910.1016/0166-3542(90)90029-72353804 93.MaranoGPupellaSPatiIMasielloFFranchiniMVaglioSVelatiCLiumbrunoGMTen years since the last"/>
 <result pre="the Chikungunya virusViruses201910.3390/v1102017530791607 96.MazzonMOrtega-PrietoAMImrieDLuftCHessLCziesoSGroveJSkeltonJKFarleighLBugertJJWrightETempertonNAngellROxenfordSJacobsMKettelerRDornerMMarshMIdentification of broad-spectrum antiviral compounds by targeting" exact="viral" post="entryViruses201910.3390/v1102017630791609 97.McCormickJBKingIJWebbPAScribnerCLCravenRBJohnsonKMElliottLHBelmont-WilliamsRLassa fever. Effective therapy with ribavirinN Engl J"/>
 <result pre="a novel double pro-drug: INX-08189. A new clinical candidate for" exact="hepatitis" post="C virus BioorgMed Chem Lett2010204850485410.1016/j.bmcl.2010.06.094 99.McGuiganCHinsingerKFarleighLPathiranaRNBugertJJNovel antiviral activity of"/>
 <result pre="Lett2010204850485410.1016/j.bmcl.2010.06.094 99.McGuiganCHinsingerKFarleighLPathiranaRNBugertJJNovel antiviral activity of l-dideoxy bicyclic nucleoside analogues versus" exact="vaccinia" post="and measles viruses in vitroJ Med Chem2013561311132210.1021/jm301778x23320521 100.MercerJHeleniusAVirus entry"/>
 <result pre="antiviral activity of l-dideoxy bicyclic nucleoside analogues versus vaccinia and" exact="measles" post="viruses in vitroJ Med Chem2013561311132210.1021/jm301778x23320521 100.MercerJHeleniusAVirus entry by macropinocytosisNat"/>
 <result pre="Res20087811612410.1016/j.antiviral.2007.10.00918061688 104.MuckerEMGoffAJShamblinJDGrosenbachDWDamonIKMehalJMHolmanRCCarrollDGallardoNOlsonVAClemmonsCJHudsonPHrubyDEEfficacy of Tecovirimat (ST-246) in Nonhuman primates infected with" exact="variola" post="virus (smallpox)Antimicrob Agents Chemother201357126246625310.1128/aac.00977-1324100494 105.MumtazNJimmersonLCBushmanLRKiserJJAronGReuskenCBEMKoopmansMPGvan KampenJJACell-line dependent antiviral activity"/>
 <result pre="al.Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of" exact="hepatitis" post="C genotype 1 patientsAnn Hepatol201211153110.1016/S1665-2681(19)31482-622166557 109.Nolte J, Cima C,"/>
 <result pre="small molecule that mimics an essential C-Terminal tripeptide of the" exact="vaccinia" post="D4 processivity factorAntivir Res201916217818510.1016/j.antiviral.2018.12.01130578797 112.ÖlschlägerSNeytsJGüntherSDepletion of GTP pool is"/>
 <result pre="for Chikungunya virus infectionAntivir Res201815010111110.1016/j.antiviral.2017.12.01229269135 114.Osuna-RamosJFReyes-RuizJMBautista-CarbajalPCervantes-SalazarMFarfan-MoralesCNDe Jesús-GonzálezLAHurtado-MonzónAMDel ÁngelRMEzetimibe inhibits dengue" exact="virus infection" post="in Huh-7 cells by blocking the cholesterol transporter Niemann-Pick"/>
 <result pre="Chikungunya virus infectionAntivir Res201815010111110.1016/j.antiviral.2017.12.01229269135 114.Osuna-RamosJFReyes-RuizJMBautista-CarbajalPCervantes-SalazarMFarfan-MoralesCNDe Jesús-GonzálezLAHurtado-MonzónAMDel ÁngelRMEzetimibe inhibits dengue virus" exact="infection" post="in Huh-7 cells by blocking the cholesterol transporter Niemann-Pick"/>
 <result pre="receptorAntivir Res201816015116410.1016/j.antiviral.2018.10.02430391500 115.ParkerSCrumpRFosterSHartzlerHHembradorELanierERPainterGSchriewerJTrostLCBullerRMCo-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with" exact="smallpox" post="vaccine does not compromise vaccine protection in mice challenged"/>
 <result pre="diagnosis, and prevention2019InfectDis Clin N Am 118.PiresMARodriguesNFSde OliveiraDBde AssisFLCostaGBKroonEGMotaBEFIn vitro" exact="susceptibility to" post="ST-246 and Cidofovir corroborates the phylogenetic separation of Brazilian"/>
 <result pre="susceptibility to ST-246 and Cidofovir corroborates the phylogenetic separation of" exact="Brazilian" post="Vaccinia virus into two cladesAntivir Res2018152364410.1016/j.antiviral.2018.02.00529427676 119.PollaraJJLasterSMPettyITDInhibition of poxvirus"/>
 <result pre="to ST-246 and Cidofovir corroborates the phylogenetic separation of Brazilian" exact="Vaccinia" post="virus into two cladesAntivir Res2018152364410.1016/j.antiviral.2018.02.00529427676 119.PollaraJJLasterSMPettyITDInhibition of poxvirus growth"/>
 <result pre="seasonality and climate changeEpidemics201910.1016/j.epidem.2019.05.00331175008 125.RosenkeKFeldmannHWestoverJBHanleyPWMartellaroCFeldmannFSaturdayGLovaglioJScottDPFurutaYKomenoTGowenBBSafronetzDUse of favipiravir to treat lassa" exact="virus infection" post="in macaquesEmerg Infect Dis2018241696169910.3201/eid2409.18023329882740 126.RothanHABahraniHAbdulrahmanAYMohamedZTeohTCOthmanSRashidNNRahmanNAYusofRMefenamic acid in combination with"/>
 <result pre="and climate changeEpidemics201910.1016/j.epidem.2019.05.00331175008 125.RosenkeKFeldmannHWestoverJBHanleyPWMartellaroCFeldmannFSaturdayGLovaglioJScottDPFurutaYKomenoTGowenBBSafronetzDUse of favipiravir to treat lassa virus" exact="infection" post="in macaquesEmerg Infect Dis2018241696169910.3201/eid2409.18023329882740 126.RothanHABahraniHAbdulrahmanAYMohamedZTeohTCOthmanSRashidNNRahmanNAYusofRMefenamic acid in combination with"/>
 <result pre="acid in combination with ribavirin shows significant effects in reducing" exact="chikungunya" post="virus infection In vitro and In vivoAntivir Res2016127505610.1016/j.antiviral.2016.01.00626794398 127.Schmidt-ChanasitJEssbauerSPetraityteRYoshimatsuKTackmannKConrathsFJSasnauskasKArikawaJThomasAPfefferMScharninghausenJJSplettstoesserWWenkMHeckelGUlrichRGExtensive"/>
 <result pre="in combination with ribavirin shows significant effects in reducing chikungunya" exact="virus infection" post="In vitro and In vivoAntivir Res2016127505610.1016/j.antiviral.2016.01.00626794398 127.Schmidt-ChanasitJEssbauerSPetraityteRYoshimatsuKTackmannKConrathsFJSasnauskasKArikawaJThomasAPfefferMScharninghausenJJSplettstoesserWWenkMHeckelGUlrichRGExtensive host sharing"/>
 <result pre="combination with ribavirin shows significant effects in reducing chikungunya virus" exact="infection" post="In vitro and In vivoAntivir Res2016127505610.1016/j.antiviral.2016.01.00626794398 127.Schmidt-ChanasitJEssbauerSPetraityteRYoshimatsuKTackmannKConrathsFJSasnauskasKArikawaJThomasAPfefferMScharninghausenJJSplettstoesserWWenkMHeckelGUlrichRGExtensive host sharing"/>
 <result pre="128.Segura GuerreroNASharmaSNeytsJKapteinSJFFavipiravir inhibits In vitro Usutu virus replication and delays" exact="disease" post="progression in an infection model in miceAntivir Res201816013714210.1016/j.antiviral.2018.10.02630385306 129.SheahanTPSimsACGrahamRLet"/>
 <result pre="vitro Usutu virus replication and delays disease progression in an" exact="infection" post="model in miceAntivir Res201816013714210.1016/j.antiviral.2018.10.02630385306 129.SheahanTPSimsACGrahamRLet al.Broad-spectrum antiviral GS-5734 inhibits"/>
 <result pre="a broad-spectrum inhibitor of bunyaviruses In vitro and in phleboviral" exact="disease" post="mouse modelsAntivir Res2018160485410.1016/j.antiviral.2018.10.01330339848 135.SmithDROggMGarrisonAYunusAHonkoAJohnsonJOlingerGHensleyLEKinchMDevelopment of FGI-106 as a broad-spectrum"/>
 <result pre="the treatment of lethal rabbitpox virus infection: a model of" exact="smallpox" post="diseaseAntivir Res201511711512110.1016/j.antiviral.2015.02.00725746331 140.van EedenPJvan EedenSFJoubertJRKingJBvan de WalBWMichellWLA nosocomial outbreak"/>
 <result pre="Geneeskd198568718721 141.VargheseFSKaukinenPGläskerSBespalovMHanskiLWennerbergKKümmererBMAholaTDiscovery of berberine, abamectin and ivermectin as antivirals against" exact="chikungunya" post="and other alphavirusesAntivir Res201612611712410.1016/j.antiviral.2015.12.01226752081 142.WaltonTEJohnsonKMMonathTPVenezuelan equine encephalomyelitisThe Arboviruses: epidemiology"/>
 <result pre="molecule GS-5734 against Ebola virus in rhesus monkeysNature201653138138510.1038/nature1718026934220 145.WestoverJBMathisATaylorRWanderseeLBaileyKWSefingEJHickersonBTJungK-HSheridanWPGowenBBGalidesivir limits" exact="Rift Valley fever" post="virus infection and disease in Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447"/>
 <result pre="Ebola virus in rhesus monkeysNature201653138138510.1038/nature1718026934220 145.WestoverJBMathisATaylorRWanderseeLBaileyKWSefingEJHickersonBTJungK-HSheridanWPGowenBBGalidesivir limits Rift Valley fever" exact="virus infection" post="and disease in Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447 146.WhitehouseERRaoAKYuYCYuPAGriffinMGormanSAngelKAMcDonaldECManlutacALPerioMAMcCollumAMDavidsonWWilkinsKOrtegaESatheshkumarPSTownsendMBIsakariMPetersenBWNovel treatment"/>
 <result pre="virus in rhesus monkeysNature201653138138510.1038/nature1718026934220 145.WestoverJBMathisATaylorRWanderseeLBaileyKWSefingEJHickersonBTJungK-HSheridanWPGowenBBGalidesivir limits Rift Valley fever virus" exact="infection" post="and disease in Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447 146.WhitehouseERRaoAKYuYCYuPAGriffinMGormanSAngelKAMcDonaldECManlutacALPerioMAMcCollumAMDavidsonWWilkinsKOrtegaESatheshkumarPSTownsendMBIsakariMPetersenBWNovel treatment"/>
 <result pre="rhesus monkeysNature201653138138510.1038/nature1718026934220 145.WestoverJBMathisATaylorRWanderseeLBaileyKWSefingEJHickersonBTJungK-HSheridanWPGowenBBGalidesivir limits Rift Valley fever virus infection and" exact="disease" post="in Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447 146.WhitehouseERRaoAKYuYCYuPAGriffinMGormanSAngelKAMcDonaldECManlutacALPerioMAMcCollumAMDavidsonWWilkinsKOrtegaESatheshkumarPSTownsendMBIsakariMPetersenBWNovel treatment of a"/>
 <result pre="disease in Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447 146.WhitehouseERRaoAKYuYCYuPAGriffinMGormanSAngelKAMcDonaldECManlutacALPerioMAMcCollumAMDavidsonWWilkinsKOrtegaESatheshkumarPSTownsendMBIsakariMPetersenBWNovel treatment of a" exact="vaccinia" post="virus infection from an occupational needlestick—San Diego, CaliforniaMMWR Morb"/>
 <result pre="in Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447 146.WhitehouseERRaoAKYuYCYuPAGriffinMGormanSAngelKAMcDonaldECManlutacALPerioMAMcCollumAMDavidsonWWilkinsKOrtegaESatheshkumarPSTownsendMBIsakariMPetersenBWNovel treatment of a vaccinia" exact="virus infection" post="from an occupational needlestick—San Diego, CaliforniaMMWR Morb Mortal Wkly"/>
 <result pre="Syrian golden hamstersAntivir Res2018156384510.1016/j.antiviral.2018.05.01329864447 146.WhitehouseERRaoAKYuYCYuPAGriffinMGormanSAngelKAMcDonaldECManlutacALPerioMAMcCollumAMDavidsonWWilkinsKOrtegaESatheshkumarPSTownsendMBIsakariMPetersenBWNovel treatment of a vaccinia virus" exact="infection" post="from an occupational needlestick—San Diego, CaliforniaMMWR Morb Mortal Wkly"/>
 <result pre="CaliforniaMMWR Morb Mortal Wkly Rep20196894394610.15585/mmwr.mm6842a231647789 147.WHO Roadmap to Nectected Tropical" exact="Diseases" post="(2012) https://unitingtocombatntds.org/wp-content/uploads/2017/11/who_ntd_roadmap.pdf 148.WHO (2016) Lassa fever in Germany. https://www.who.int/csr/don/23-march-2016-lassa-fever-germany/en/"/>
 <result pre="147.WHO Roadmap to Nectected Tropical Diseases (2012) https://unitingtocombatntds.org/wp-content/uploads/2017/11/who_ntd_roadmap.pdf 148.WHO (2016)" exact="Lassa fever" post="in Germany. https://www.who.int/csr/don/23-march-2016-lassa-fever-germany/en/ 149.collab: WHOA global strategy to eliminate"/>
 <result pre="fever in Germany. https://www.who.int/csr/don/23-march-2016-lassa-fever-germany/en/ 149.collab: WHOA global strategy to eliminate" exact="yellow fever" post="epidemics 2017–20262018GenevaWorld Health Organization 150.WHO (2019) Update on ebola"/>
 <result pre="Virol201791e00838-1710.1128/jvi.00838-1728659488 152.YoonJ-JTootsMLeeSLeeM-ELudekeBLuczoJMGantiKCoxRMSticherZMEdpugantiVMitchellDGLockwoodMAKolykhalovAAGreningerALMooreMLPainterGRLowenACTompkinsSMFearnsRNatchusMGPlemperRKOrally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and" exact="respiratory" post="syncytial virusesAntimicrob Agents Chemother201862e00766-1810.1128/AAC.00766-1829891600 153.Zanetta P (2019) Dandelion extract"/>
</results>
